PTO/S8/08A (06-00)

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a or form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 3

collection of information unless it displays a	valid OMB control number.
Application Number	10/596,738
Filing Date	06/22/2006
First Named Inventor	VOORSPOELS, J.
Group Art Unit	1615
Examiner Name	
Attomey Docket Number	TIP-0048USPCT

#### U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS							
		U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Pages, Columns, Lines,	
Examiner Initials	Cite No.1		d Code <sup>2</sup> f known)	of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear	
	5,993, 858		Port Systems, L.L.C.	11-30-1999			
		6,008,228		Hoffman-La Roche Inc.	12-28-1999		
	6,248,775 B1		G.D. Searle & Co.	06-19-2001			
		2003/004434	A1	Gao, P.	03-06-2003		
		6,054,136		Farah el al.	04-25-2000		
		6,312,704		Farah et al.	11-06-001		
		6,274,727		Maul et al.	08-14-2001		
		2004/0013697		Berndl et al.	01-22-2004		

#### FOREIGN PATENT DOCUMENTS

		Foreign	Patent Docume	nt	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No.1	Office <sup>3</sup>	Number <sup>4</sup> Ki	ndCode <sup>5</sup>	Applicant of Cited Document	mm-dd-yyyy passages or relevar figures appear		T <sup>6</sup>
		EP	0435450	B1	ICI Americas Inc.	10-12-1994		
		EP	0715618	B1	G.D. Searle & Co.	12-16-1998		
		EP	1170003	B1	Hovid SDN BHD	04-05-2006		
		JP	2001- 151699		Nippon Kayaku Co. LTD (English abstract included & claim translation)	06-05-2001		
		wo	95/07596	A1	Abbott Laboratories	03-23-1995		
		wo	95/08983	A1	Gatte-Fosse S.A	04-06-1995	(US 6312704 and US 6054136 family members provided)	
		wo	96/39142	A1	F. Hoffman-La Roche AG	12-12-1996		
		wo	98/22106	A1	Abbott Laboratories	05-28-1998		
		wo	98/22094	A2	Merck Patent GMBH	05-28-1998		
		wo	99/06043	A1	Pharmacia & Upjohn Company	02-11-1999		

Examiner							Date						
Signature							Consi	iered					

\*EXAMINET: Initial of reference considered, whether or not citation is in conformance with MPEP 608. Draw line through cutation of not in conformance and not considered include copy of their form with neet communication to applicant and not considered include copy of their form with neet communication to applicant in Unique cutation designation number. 25ee statubed Kristie of U.S. Patient Documents. 5:Enter Office that issued the document, by the low letter code (WINPD Standard ST.3.) 4; For Japanese patient documents, he indication of the year of the reign of the Emperor must proceed the serial number of the patient document. Sknid of document by the appropriate sprinciples in statistical state of the Emperor must proceed the serial number of the patient document. Sknid of document with the sprinciple in the state of the st

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0551-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to	o a collection of information unless it displays a	
bstitute for form 1449A/PTO	Application Number	10/596,738
	Cities Date	00/00/0000

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 3

a conection of illiormation unless it displays a	valid OMB corlidor runber.
Application Number	10/596,738
Filing Date	06/22/2006
First Named Inventor	VOORSPOELS, J.
Group Art Unit	1615
Examiner Name	
Attomey Docket Number	TIP-0048USPCT

				U.S. PATENT DOCUMENTS		
		U.S. Patent Document			Date of Publication	Pages, Columns, Lines,
Examiner Initials	Cite No.1		d Code <sup>2</sup> known)	Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear
						\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \

				FOR	EIGN PATENT DOCUMENTS			
Examiner Initials	Cite			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>	
		wo	99/06044	A1	Pharmacia & Upjohn Company	02-11-1999		
		wo	99/67417	A1	The Secretary, Department of Health and Human Services, USA	12-29-1999		
		wo	00/33862	A1	Pharmasolutions, Inc.	06-19-2008		
		wo	01/34119	A2	Abbott Laboratories	05-17-2001		
		wo	01/91727	A2	BASF Aktiengesellschaft	12-06-2001		
		wo	02/07712	A2	Pharmacia & UpJohn Company; Sugen, Inc.	01-31-2002		
		wo	02/36110	А3	Boehringer Ingelheim Pharmaceuticals, Inc.	05-10-2002		
		wo	03/049746	А3	Tibotec Pharmaceuticals, Ltd.	06-19-2003		
		wo	03/106461	A2	Tibotec Pharmaceuticals, Ltd.	12-24-2003		
		wo	98/22094		Merck Patent GMBH	05-28-1998	US 6274727 family member provided	
		wo	01/91727	11.7	BASF Aktiengesellschaft	05/29/2001	US 2004/0013697 family member	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

and not considered. Include copy of this form with next communication to applicant.

Unique beloan designation number is See attacked Kinds of U.S. Patient Documents. Is Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patient documents, the indication of the year of the regin of the Emport must precode the serial number of the patient documents. After the consens of the Competent St. Patient and Table 1 and the Competent St. Patient Pa

PTO/SB/08A (06-00)

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a corr form 1449APTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 3 of 3

ollection of information unless it displays a valid OMB control number:							
Application Number	10/596,738						
iling Date	06/22/2006						
irst Named Inventor	VOORSPOELS, J.						
Group Art Unit	1615						
xaminer Name							
Attomey Docket Number	TIP-0048USPCT						

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
	l	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T <sup>2</sup>
Initials*	No.1	publisher, city and/or country where published	
		CHARMAN, W.N., "Lipids, Lipophilic Drugs, and Oral Drug Delivery-Some Emerging Concepts.", Journal	
		of Pharmaceutical Sciences, August 2000, Vol. 89, No. 8, pages 967-978.	
		CONSTANTINIDES, P.P., "Lipid Microemulsions For Improving Drug Dissolution And Oral Absorption:	
	l	Physical and Biopharmaceutical Aspects.", Pharmaceutical Research, 1995, Vol. 12, No. 11, pages 1561-	
		1572, Plenum Publishing Corporation.	
		GHOSH et al., "Potent HIV Protease Inhibitors Incorporating High-Affinity Pr Ligands and (R)-	
		(hydroxyethylamino)sulfonamide Isotere.", Biogranic & Medicinal Chemistry Letters, 1998, Vol. 8, pages	
		687-690.	
		HUMBERSTONE et al., "Lipid-based Vehicles For The Oral Delivery Of Poorly Water Soluble Drugs.",	
		Advanced Drug Delivery Reviews, 1997, Vol. 25, pages 103-128.	
		POUTON, C. W., "Formulation Of Self-Emulsifying Drug Delivery Systems.", Advanced Drug Delivery	
		Reviews, 1997, Vol. 25, pages 47-58.	
		SWENSON et al., "Means to Enhance Penetration: (2) Intestinal Permeability Enhancement For Proteins,	
	1	Peptides and Other Polar Drugs: Mechanisms and Potential Toxicity.", Advanced Drug Delivery Reviews,	
		1992, Vol. 8, pages 39-92, Elsevier Science Publishers B.V.	
	_		
_			
	_		

F

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademan's Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.